Stock info Epizyme Inc | Filter  Basic-Info

Epizyme Inc

Past year was a negative year for Epizyme Inc investors

The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 27 percent. Over the period 2011-2016 the stock lost a modest 0 percent. Epizyme Inc's revenues between 2011 and 2015 were far from constant and moved between 45,22 million dollars and 2,56 million dollars. Epizyme Inc's net results between 2011 and 2015 were far from constant and moved between -20,96 million dollars and -132,38 million dollars.

Epizyme Inc primarily operates in the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

Over the past 5 years the American company paid out dividends.

Healthy financed: not so much debt Epizyme Inc

At the end of 2015 the American company had a balance sheet of around 217,9 million dollars. 48,37 million dollars (22,2 percent of the total balance sheet) was financed by debt. At the end of 2016 the American company was traded with a price/earnings-ratio of around -6. So investors paid -6 times the company's 2015's EPS. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the American company's market capitalization equaled around 616,31 million dollars. At the end of 2015 the American company had around 39,84 million stocks listed on the exchanges.

All the annual reports of Epizyme Inc are available here. More information about Epizyme Inc can be found it's website. .